Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challengesArchived
In Belgium, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the national schedule in 2007.
Hanquet G, Lernout T, Vergison A, Verhaegen J, Kissling E, Tuerlinckx D et al. Vaccine 2011; 29: 2856–64.
The early impact of PCV7 vaccination on paediatric invasive disease was estimated by comparing pre- and post-vaccination incidence from national surveillance. In children <2 year-olds, vaccine-serotype incidence declined by 96% but non-vaccine-types increased 2–3-fold. Overall invasive disease decreased by 23–46%, depending on adjustment for under-reporting and pre-vaccine trends.
Non-vaccine-types 1 and 19A had increased before PCV7 use, suggesting the contribution of other factors. Estimation of PCV7 impact comparing pre- and post-vaccination data should adjust for pre-vaccine trends, and serotype dynamics need further exploration.
Decline in early childhood respiratory tract infections in the norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccinationArchived
27 Nov 2012 - The study design and analysis controlled for influence of potentially confounding trends, such as improvement of day-care carriage and decreasing prevalence of smoking during the study period.
A review of the effect of immunization programs on antimicrobial utilizationArchived
16 Oct 2012 - Antimicrobial stewardship policies are increasingly being implemented as a measure to prevent and control antimicrobial resistance.
Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in childrenArchived
16 Aug 2012 - The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.